CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity

• Main Authors: Edward A. Clark, Natalia V. Giltiay
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-09-01
• Series: Frontiers in Immunology
• Subjects: CD22; B cells; autoimmunity; antigens; TLR7; T cell dependent
• Online Access: https://www.frontiersin.org/article/10.3389/fimmu.2018.02235/full

CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets regulated by CD22 or Siglec G (2–4). This review is an attempt to highlight recent and possibly forgotten findings. We also describe the role of CD22 in autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE).